new "designer estrogen," Evista
January 1999
Lilly is now promoting their new "designer estrogen," Evista.
It'll be used as an alternative to estrogen...to prevent osteoporosis in postmenopausal women.
Evista (raloxifene) is a selective estrogen receptor modulator...in the same class as tamoxifen. It mimics the effects of estrogen in some tissues...but not in others.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive